<DOC>
	<DOCNO>NCT00021164</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may make body build immune response kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness vaccine therapy treat patient metastatic cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether immunologic response obtain HLA*0201-expressing patient metastatic cancer treat telomerase : 540-548 peptide vaccine emulsify Montanide ISA-51 . - Determine vaccine strategy ( frequency , schedule , dose ) best future study patient . - Determine toxicity treatment patient . - Determine whether prior immunization telomerase : 540-548 peptide vaccine result increase clinical response interleukin-2 patient melanoma . OUTLINE : This randomize study . Patients stratify accord disease ( metastatic cutaneous melanoma v tumor type ) . Patients randomize one three treatment arm . - Arm I : Patients receive telomerase : 540-548 peptide vaccine emulsify Montanide ISA-51 subcutaneously ( SC ) day 1 week 1-4 7-10 . Patients also undergo leukapheresis 3 hour baseline course treatment . - Arm II : Patients receive telomerase : 540-548 peptide vaccine emulsify Montanide ISA-51 SC day 1 week 1 , 4 , 7 , 10 . Patients also undergo leukapheresis 3 hour baseline , vaccine week 4 , course treatment . - Arm III : Patients receive telomerase : 540-548 peptide vaccine emulsify Montanide ISA-51 SC day 1-4 week 1 , 4 , 7 , 10 . Patients undergo leukapheresis arm II . Treatment arm repeat every 13 week 4-6 course absence disease progression unacceptable toxicity . Patients complete response ( CR ) receive 1 additional course treatment achieve CR . Eligible melanoma patient progressive disease vaccine alone 3 arm may receive interleukin-2 ( IL-2 ) combine vaccine arm II . Beginning day immunization , IL-2 administer IV 15 minute every 8 hour 4 day week 1 , 4 , 7 , 10 maximum 12 dos . Patients continue experience disease progression combine vaccine IL-2 therapy go study 2 course combine therapy . Patients follow 3 week . PROJECTED ACCRUAL : A total 90-162 patient ( 30-54 per treatment arm ; 45-81 per stratum ) accrue study within less 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Presenting evaluable metastatic cancer Refractory standard treatment OR Postradiation malignant glioma HLAA*0201 expression PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 90,000/mm^3 Hepatic : Bilirubin great 1.6 mg/dL AST/ALT le 3 time normal Hepatitis B surface antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No cardiac ischemia stress thallium comparable test* No prior myocardial infarction* No cardiac arrhythmias* NOTE : *Patients receive interleukin2 ( IL2 ) Pulmonary : No obstructive restrictive pulmonary disease ( patient receive IL2 ) Immunologic : HIV negative No autoimmune disease know immunodeficiency disease No active primary secondary immunodeficiency Other : No active major medical illness* No active systemic infection Not pregnant Negative pregnancy test Fertile patient must use effective contraception NOTE : *Patients receive IL2 PRIOR CONCURRENT THERAPY : Biologic therapy : No prior telomerase : 540548 peptide immunization Chemotherapy : Recovered prior chemotherapy Endocrine therapy : No requirement systemic steroid therapy Radiotherapy : See Disease Characteristics Recovered prior radiotherapy Surgery : Not specify Other : At least 3 week since prior systemic therapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>